Last updated: 2026-09-06 01:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioNexus Gene Lab Corp. (BGLC) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $1.43, with a market capitalization of $4.31M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.07 to $6.10. This page covers its latest market performance, valuation, price trends and company information.
$4.31M | |
$1.53 | |
$267.60 | |
$1.07 | |
$1.47 | |
741.00 | |
-- | |
-- | |
$6.10 | |
$1.07 | |
-- | |
-- |
BioNexus Gene Lab Corp. (BGLC) last closed at $1.47 as of 2026-09-04 23:31:00, unchanged from the previous close of $1.47.
During the latest regular trading session, BGLC traded between $1.07 and $267.60, with a volume of 741.00 shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, BioNexus Gene Lab Corp. (BGLC) moved from $1.48 to $1.43, representing a decline of 3.65% ($0.05).
The stock traded between $1.40 and $1.53 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 5.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.1%
BGLC is currently trading at $1.43, placing it 7.1% of the way from its 52-week low of $1.07 to its 52-week high of $6.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioNexus Gene Lab Corp. (BGLC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.